An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence.
A 22-amino-acid-long multibranched peptide construct (CLV) derived from the cleavage region (KIEPLGVAPTKAKRR*VVQREKR*) of the human immunodeficiency virus (HIV) type-1 envelope precursor inhibits HIV infection (Virology, 1996, 223, 406-408). We attempted to characterize its activity for Env expressed via a recombinant vaccinia virus (rVV): gp 160 cleavage was delayed, but not impaired, in the presence of CLV (10 microM), whereas neither Env production nor Env membrane expression was significantly altered. Through the synthesis of analogs, we concluded that the presence of a cleavage sequence was required for inhibition of syncytium formation by CLV in rVV-infected CD(4+) cell cultures: indeed, a single amino acid residue substitution (R* > S) in the cleavage sites presented by CLV abolished its activity. Other analogs allowed us to further determine the region of CLV which mediates its activity. The ability of a radiolabeled CLV analog to enter cells was also shown. Although, these data strongly suggest that CLV acts on Env fusogenicity at least partially through interference with gp160 processing.
CNRS, Faculté de Médecine Nord, Marseille, France.
R
R
Barbouche
J M
JM
Sabatier
E
E
Fenouillet
D000595:Amino Acid Sequence; D000818:Animals; D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D002460:Cell Line; D002462:Cell Membrane / Q000821:virology; D002478:Cells, Cultured; D006224:Cricetinae; D015686:Gene Products, env / Q000187:drug effects / Q000378:metabolism*; D015726:Giant Cells / Q000821:virology; D019302:HIV Envelope Protein gp160 / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D011498:Protein Precursors / Q000737:chemistry / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects
D019380:Anti-HIV Agents; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D010455:Peptides; D011498:Protein Precursors